Prosecution Insights
Last updated: November 04, 2026
Application No. 17/603,260

INHIBITORS OF CD40-CD154 BINDING

Non-Final OA §112
Filed
Oct 12, 2021
Priority
Apr 12, 2019 — provisional 62/833,473 +1 more
Examiner
KENYON, JOHN S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tonix Pharmaceuticals Holding Corp.
OA Round
2 (Non-Final)
80%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
766 granted / 960 resolved
+19.8% vs TC avg
Strong +18% interview lift
Without
With
+18.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
47 currently pending
Career history
1010
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
16.1%
-23.9% vs TC avg
§102
22.1%
-17.9% vs TC avg
§112
42.3%
+2.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 960 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicants’ claim amendments render moot the prior art rejection of record. Examiner extended the Markush search to the full scope of instant claims 1 and 57-58. The Election of Species Requirement will be withdrawn once Applicants overcome the rejections, below. All claims have been examined on the merits. This constitutes a Non-Final Office Action given new rejections, below. Current Status of 17/603,260 This Office Action is responsive to the amended claims of 23 April 2026. Claims 1-58 and 63-67 have been examined on the merits. Priority The effective filing date is 12 April 2019. Response to Arguments The Examiner acknowledges receipt of and has reviewed Applicants’ claim amendments and Reply of 23 April 2026. Applicants revised the claims removing C1alkenyl and C1alkynyl as requested, thereby rendering moot the indefiniteness rejection of record. Applicants removed parentheticals surrounding limitations in the claims, as requested, thereby rendering moot the indefiniteness rejection of record. Applicants added “R3 is absent” as an alternative embodiment in parent claim 1 thereby rendering moot the indefiniteness rejection and rejection under 35 USC 112(d) of record. Applicants removed “prodrug” from the claims thereby rendering moot the anticipatory prior art rejection of record. New Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-56 and 63-65 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. The genus of formula I of independent claim 1 is broad. Ring A can have either a carbon (C) or nitrogen (N) at any one or more positions X1-X4 [this is interpreted as presenting 24 = 16 possible outcomes]. Moreover, ring A can have single and double bonds with varying patterns of C-C or C and N, and also can have S, O, N, or CH, to name a few exemplary embodiments at position R4 [at least nine possible outcomes]. Claim 1 permits ring A to be 6-membered or 5-membered aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycloalkyl rings [at least 6 different outcomes]. Thus, ring A alone presents 16 + 9 + 6 = 31 total possible outcomes*. Similarly, ring B is just as varied, permitting multiple species with C or N at X5-X6 [interpreted as 22 = 4 possible outcomes]. R7 is just as varied as R4 [5 different outcomes]. Claim 1 permits ring B to be 6-membered or 5-membered aryl, heteroaryl [3 different outcomes]. Thus, ring B alone presents 4 + 5+ 3 = 12 total possible outcomes*. Also, ring C is just as varied, permitting C or N at X7 and X8 [interpreted as 22 = 4 possible outcomes]. R8 is just as varied as R4 and R7 [5 different outcomes]. Claim 1 permits ring C to be 6-membered or 5-membered aryl, heteroaryl [3 different outcomes]. Thus, ring C alone presents 4 + 5 + 3 = 12 total possible outcomes*. Furthermore, ring D is varied, permitting C or N at X9 and X10 [interpreted as 22 = 4 possible outcomes] with R13 being just as varied as R4, R7, and R8 [represents 5 different outcomes]. Claim 1 permits ring D to be 6-membered or 5-membered aryl, heteroaryl [represents 3 different outcomes]. Thus, ring D alone presents 4 + 5 + 3 = 12 total possible outcomes*. The L1 and L2 and L3 variables introduce additional variability to the genus formula I. Claim 1 permits L1 to be a single bond, absent, amide, reverse amide, a heterocycloalkyl ring, or form a ring with R3 of ring A. Variable L2 and L3 has these attributes plus additional alternative embodiments. Put another way, L1 presents 6 different outcomes; L2 presents 13 different outcomes; and L3 presents 13 different outcomes. *The actual number of possibilities is much more complicated, but the Examiner counts at least 99 different permutations/combinations/possibilities from rings A, B, C, and D plus L1-L3, as described, above. Additionally, some of the substituent variables such as R1 and R2 can optionally form a fused ring with the existing rings of genus formula I, which adds to the variability. R10 and R11 can join together with ring D to make a fused ring as well. Against the backdrop of the variability of species of genus formula I of instant claim 1 (at least 99 different species representing different permutations of each alternative embodiment from ring A-D and L1-L3, per, above), above, Applicants show evidence of actual possession of far fewer species. This written description rejection is centered on the lack of evidence in the Specification that Applicants were in actual possession of a representative number of at least 99 distinct species of the broad genus formula I, as claimed in claim 1 and described, above. While Applicants have shown actual possession of species of examples 1-51 (pages 41-106 of the Specification), these are not representative of the sheer breadth** of the genus formula I of claim 1, per, above. See MPEP 2163. (**Realize, too, the actual math computing the total permutations or combinations of alternative embodiments from each of rings A-D and L1-L3 would be much higher than 99). Therefore, claim 1 is rejected under 35 USC 112(a) written description since Applicants’ claim 1 encompasses more species than they actually demonstrate actual possession of in their Examples 1-51 of the Specification. Claims 2-56 and 63-65 are similarly rejected under 35 USC 112(a) written description since these claims refer back to claim 1 but do not remedy the rationale underpinning the basis for rejecting claim 1. How to render moot this rejection: please narrow the genus of formula I of claim 1 to encompass the Examples 1-51 of the Specification, for which Applicants have proof of actual possession. Applicants’ Examples 1-51 of the Specification seem to correspond to the species of claims 57-58, so the claims 57-58 are not rejected under 35 USC 112(a). Claims 64-65 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification and/or prior art, while being enabling for treating or ameliorating the diseases disclosed within claim 65, does not reasonably provide enablement for treating, ameliorating, or preventing any/undefined scope of: autoimmune disease, or other immune-related diseases, atherosclerotic disorders, neurodegenerative disorders, inflammatory disease, prevention of transplant rejection, and treatment of malignancies according to instant claim 64. The specification and/or prior art do not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make/use the invention commensurate in scope with these claims. The Wands Factors used in an (scope of) enablement rejection include (per MPEP 2164.01(a)): The breadth of the claims: The method claims 64-65 are each drawn to a method of treating, ameliorating, or preventing the diseases of the claims 64-65 by administering the compound of formula I of claim 1. The broadest reasonable interpretation (BRI) of instant claim 64 is drawn to treating, ameliorating, or preventing an undefined scope of diseases of: autoimmune disease, or other immune-related diseases, atherosclerotic disorders, neurodegenerative disorders, inflammatory disease, prevention of transplant rejection, and treatment of malignancies according to instant claim 64. The nature of the invention: The invention belongs to biotechnology, more specifically, immunotherapy involving pharmaceutical compositions comprising: the compounds of genus formula I of instant claim 1 which modulate CD40-CD154. As stated in the Background section of the Specification, the CD-40-CD154 are involved in immune T cell signaling. Therefore, the Examiner is interpreting the broadest reasonable interpretation (BRI) of the method claims 64-65 to include treating, ameliorating, or preventing any disease of claims 64-65. The state of the prior art: Furthermore, there is no known prior art that would support preventing the diseases of claims 64-65. For example, the reference LUPUS (Lupus Research Alliance. “What is Lupus?”. Available to the public: 3 May 2017. Accessed 25 September 2026. Available from: < https://www.lupusresearch.org/about-lupus/what-is-lupus/ >), discloses that lupus is unpredictable in nature (see page 4 of 7 under the heading “Why is lupus so complex?”). This begs the question: If we cannot predict who will get lupus, how can we prevent it? Moreover, the reference T1D (Monzavi, Roshanak. “Symptoms, Treatment and Prevention of Type 1 Diabetes.” Available to the public: 13 July 2015. Accessed: 25 September 2026. Available from: < https://www.chla.org/blog/advice-experts/symptoms-treatment-and-prevention-type-1-diabetes > ), discloses that there are no known therapies that can alter the immune system and prevent it from destroying beta cells; hence, there is no known way to prevent Type 1 diabetes (page 4 of 7). Hence, if these two exemplary diseases of claims 64-65 cannot be prevented, the broad scope of diseases of these claims as drafted also cannot be prevented. The level of one of ordinary skill: The level of one of ordinary skill includes the knowledge/skill to engage in a reasonable amount of experimentation to make and use the pharmaceutical compositions of claim 1 based on the disclosure in the Specification (pages 1-2 and pages 41-106 and page 113 of the Specification). The one of ordinary skill also has the knowledge to engage in a reasonable amount of experimentation to treat or ameliorate some diseases, such as cardiovascular disease. However, no one has skill to engage in the undue burdensome level of experimentation required to provide guidance/enablement for treating, ameliorating, or preventing the unlimited scope of diseases/disorders of the claims 64-65. The level of predictability in the art: The art is predictable to make the instantly claimed compounds and pharmaceutical compositions. However, the art does not provide predictability as to which diseases and disorders can be prevented. To generate this level of guidance, one has to engage in undue burdensome experimentation (since no predictability in the art) to test the pharmaceutical composition against every disease of claims 64-65. This level of experimentation would be required to match the scope of instant claims 64-65. The amount of direction provided by the inventor: Inventors have provided direction as to making the pharmaceutical compound and composition (pages 1-2 and pages 41-106 and page 113 of the Specification). Inventors have also provided direction as to using the pharmaceutical composition to treat or ameliorate (but not prevent) the diseases of claim 65 (pages 1-2 and pages 41-106 and page 113 of the Specification). The existence of working examples; and Applicants’ Specification provides guidance/enablement with working examples of how Applicants synthesized their compounds of genus formula I (pages 41-106 of the Specification). Moreover, Applicants have guidance/enablement in their Specification for treating and/or ameliorating the diseases of claim 65 by administering the instant pharmaceutical compositions of the instant claims (pages 1-2 and pages 41-106 and page 113 of the Specification). This guidance does not support preventing any of the diseases of the claims 64-65. The quantity of experimentation needed to make or use the invention based on the content of the disclosure: Applicants’ invention requires a high level/quantity of experimentation to make/use the invention in order to ascertain what diseases of claims 64-65 can be prevented by administering a compound of instant claim 1. While Applicants have provided guidance in their Specification for making the pharmaceutical compound and composition of claim 1, they have not provided enough evidence that said pharmaceutical composition can be used to prevent the scope of diseases or disorders per the BRI of instant claims 64-65. At best, the Specification does provide enablement/guidance for using the instantly claimed pharmaceutical composition to treat or ameliorate (not prevent) the diseases of claim 65 (pages 1-2 and pages 41-106 and page 113 of the Specification). Therefore, claims 64-65 are both rejected under 35 USC 112(a) for lacking scope of enablement for the scope of preventing the diseases or disorders of claims 64-65. To render moot this scope of enablement rejection: Applicants should delete “prevent” and/or “prevention”/”preventing” from the claims. Moreover, Applicants should define the specific scope of diseases treated or ameliorated within claim 64. The best way to do that, is to roll the limitations from claim 65 (Markush limitation format) into claim 64. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 66-67 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 66 is a method claim which does not disclose the claim number of the compound used in the claim 66 method. This renders the metes and bounds of claim 66 undefined (hence rendering claim 66 indefinite under 35 USC 112(b)). The artisan does not know what compounds from what claim number(s) are used in the method of claim 66. Could this be the compounds of claim 1? Please revise claim 66 to tell the artisan what compound of what claim number is being used in the method of claim 66. Claim 67 is similarly rejected as indefinite under 35 USC 112(b) since this claim refers back to claim 66 but does not remedy the rationale underlying the basis for rejecting claim 66. Conclusion Claims 1-56 and 63-67 are not presently allowable as written. Claims 57-58 are presently allowable as written. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S KENYON whose telephone number is (571)270-1567. The examiner can normally be reached Monday-Friday 10a-6p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Oct 12, 2021
Application Filed
Apr 03, 2025
Non-Final Rejection mailed — §112
Oct 29, 2025
Response after Non-Final Action
Apr 23, 2026
Response Filed
Oct 05, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780804
FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR
4y 3m to grant Granted Nov 03, 2026
Patent 12780823
PROCESS FOR THE PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Patent 12780806
XANTHINE OXIDASE INHIBITOR
3y 0m to grant Granted Nov 03, 2026
Patent 12780786
HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF
2y 12m to grant Granted Nov 03, 2026
Patent 12773458
DIRECTED CONJUGATION TECHNOLOGIES
4y 6m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
80%
Grant Probability
98%
With Interview (+18.1%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 960 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month